Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The United States Department of Health and Human Services has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units. CHEN, STACY BROWN is the busiest examiner, with 1 pending matter, so the examination activity is divided between separate channels.
Counsel should coordinate biotechnology and pharmaceutical terminology across the matters while preparing separate responses to each examiner’s record. The distinct art-unit assignments make application-specific analysis important, particularly for claim scope and technical evidence. A centralized review of specification support can improve consistency, but the available data does not show a repeated examiner assignment that would support one uniform response strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
| GIAMMONA, FRANCESCA FILIPPA | 1 | 37.3% | +58.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031165 | MASSIVELY PARALLELED MULTI-PATIENT ASSAY FOR PATHOGENIC INFECTION DIAGNOSIS AND HOST PHYSIOLOGY SURVEILLANCE USING NUCLEIC ACID SEQUENCING | GIAMMONA, FRANCESCA FILIPPA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18659639 | EPSTEIN-BARR VIRUS VACCINES | CHEN, STACY BROWN | 86d |
| 18031165 | MASSIVELY PARALLELED MULTI-PATIENT ASSAY FOR PATHOGENIC INFECTION DIAGNOSIS AND HOST PHYSIOLOGY SURVEILLANCE USING NUCLEIC ACID SEQUENCING | GIAMMONA, FRANCESCA FILIPPA | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18659639 | EPSTEIN-BARR VIRUS VACCINES | CHEN, STACY BROWN | 1672 | §103DP | Non-Final OA | 86d | Pending | May 09, 2024 |
| 18031165 | MASSIVELY PARALLELED MULTI-PATIENT ASSAY FOR PATHOGENIC INFECTION DIAGNOSIS AND HOST PHYSIOLOGY SURVEILLANCE USING NUCLEIC ACID SEQUENCING | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103§112 | Final Rejection | — | Pending | Apr 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe United States Department of Health and Human Services has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Stacy Brown Chen has the most, with 1 of The United States Department of Health and Human Services's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
